Abstract. The present study was aimed to identify proteins associated with signaling pathways involved in chemoresistance, and establish a predictive model for chemoresistance in gastric cancer patients after radical surgery. A total of 140 clinically-staged III gastric cancer samples from patients after D2 radical gastrectomy were enrolled in the present study. Protein Pathway Array (PPA) and 286 antibodies were used to assess the protein expression in tumor tissues of patients. The Significance Analysis of Microarray (SAM) software and clustering and discriminant analysis were used to identify differentially expressed proteins between chemosensitive and chemoresistant subsets, and a predictive model for chemoresistance was established using the independent predictive factors. The Ingenuity Pathway Analysis (IPA) software was also used to investigate the relationship between proteins and the signaling transduction network. A total of 23 proteins were differentially expressed between 67 chemosensitive and 73 chemoresitant tumor tissues. Six proteins including PLK1 and DACH1 were independent risk factors for chemoresistance. A predictive model for chemoresistance by these proteins was established, and the accuracy, the sensitivity, and the specificity of this modal was 89.3, 90.3 and 88.2%, respectively. In addition, the present study revealed that differentially expressed proteins were closely related to cellular activity, DNA methylation and DNA damage and repair, and also involved in the ERK/MAPK, Wnt/β-catenin, PI3K/AKT, apoptosis and p53 signaling pathways. In conclusion, the predictive model established by PPA may be an effective detection system for predicting the chemosensitivity of gastric cancer patients after D2 gastrectomy.
Introduction
Worldwide, gastric cancer is the fourth most common malignant tumor, accounting for ~8% of new cancer cases (1) . It is the third leading cause of cancer-related mortality, and the gastric cancer incidence in China accounts for nearly half of all worldwide cases (2) .
Currently, surgical resection is possibly the only modality for a cure. However, since 70-90% of gastric cancer patients are first diagnosed at an advanced stage, surgical excision alone could not achieve a cure. Adjuvant chemotherapy has been adopted as the standard treatment for advanced cancer for disease-free survival and overall survival (3) (4) (5) (6) . The MAGIC trial revealed that the 5-year survival rate of patients receiving adjuvant chemotherapy was significantly higher than those undergoing resection only (36 vs. 23%) (7) .
The chemotherapeutic drugs 5-fluorouracil (5-FU), cisplatin and paclitaxel are widely used anticancer agents. However, chemotherapeutic drug resistance is a major cause of treatment failure in patients with cancer. Previous studies suggested a variety of resistance mechanisms in cancer cells underlying the resistance to chemotherapeutic drugs. The methylation of MLH1 promoter (8) , the overexpression of Bcl-2 (9), Bcl-xL (9, 10) and Mcl-1 (11) , and the increased activity of deoxyuridine triphosphatase (DUT) have been found to be associated with drug resistance to 5-FU. AKT (12) , c-ABL (13) and P53 signaling (14) , as well as the proteins are related to drug resistance to cisplatin. To identify the drug sensitivity of gastric cancer patients in a chemotherapy regimen, and to choose a personalized treatment plan for them are currently essential for physicians. The Protein Pathway Array (PPA) technology is a proteomic method that can globally characterize proteins and identify changes in protein expression (15) . In the present study, the PPA method was used to identify differentially expressed proteins which contributed to chemotherapy resistance and were involved in signaling pathways in patients with gastric cancer. In addition, the independent risk factors among proteins were screened by multivariable logistic regression analysis. Moreover, the prediction model for chemotherapy resistance was built based on the risk factors and risk coefficient. The present study may help clinicians to develop an individualized course of treatment for patients with gastric cancer.
Materials and methods
Patients and samples. From February 2008 to July 2010, a total of 140 patients with clinical stage III gastric cancer (7th AJCC) undergoing D2 radical gastrectomy and postoperative chemotherapy at the First Hospital of Jilin University were enrolled in the present study. All patients were given a written informed consent document before treatment. All patients were followed up for at least 2 years: in the first year, the patients were followed-up for disease status, physical examination, serum tumor marker and abdominal ultrasonography every 3 months, and a routine CT scan of the abdomen every 6 months; in the second year, disease status, physical examination, serum tumor marker and abdominal ultrasonography every 6 months, and a routine CT scan of the abdomen each year. Disease-free survival in patients was the period after curative treatment when no disease could be detected.
All tumor samples were resected from freshly biopsied tumor specimens: ~3 x 3 x 5 mm 3 of tumor tissues were obtained to avoid necrotic tumor tissues and the surrounding tissues, and the tumor tissues were frozen in liquid nitrogen for 24 h, and stored at -80̊C. The other specimens were fixed in neutral-buffered formalin, embedded in paraffin, and confirmed histologically by two pathologists for tumor location, tumor size, depth of invasion, degree of lymph node metastasis and histological type.
Total protein extraction. The 3 x 3 x 5 mm 3 frozen tissues were ground and homogenized. Then, the protein concentration was quantified by the bicinchoninic acid (BCA) method (Pierce, Rockford, IL, USA) and the solution was adjusted to ~1 µg/µl. SDS-PAGE for protein separation. SDS-PAGE 10% gels were prepared. The protein solution was heat denatured at 95̊C for 5 min. Approximately 300 µl of protein solution with a commercial protein ladder [8 µl; BenchMark™; Invitrogen, Carlsbad, CA, USA)] were subjected to SDS-PAGE using 100 v for 30 min by the stacking gel and 130 v by the separating gel. The proteins on the gel were transferred to a nitrocellulose membrane for 2 h at 100 v. The membranes were stained with Ponceau S to confirm successful transfer.
Antibodies used in PPA analysis. A total of 286 antibodies were used to assess the protein expression involved in multiple pathways including cell proliferation and apoptosis, cell invasion and metastasis, cell cycle, cell metabolism, cell resistance and angiogenesis.
Phosphorylation-specific antibodies were obtained from Cell Signaling Technology, except for p-protein kinase Cα (Ser657) which was obtained from Upstate Biotech (Lake Placid, NY, USA), and p-Met (Tyr1234), p-c-Jun kinase (G-7) and p-focal adhesion kinase (Tyr397) which were obtained from Santa Cruz Biotechnology (Santa Cruz, CA, USA). The non-phosphorylation-specific antibodies including Stat1, HER2/ErbB2, β-catenin, p44/42 mitogen-activated protein kinase [MAPK; extracellular signal-regulated kinase (Erk)1/2], Akt, Notch4, eIF4B, NF-κB p50, cAMP responsive element binding, estrogen receptor α, Bcl-xL, RIP, aurora A/AIK, matrix metalloproteinase-9 and Snail were purchased from Cell Signaling Technology. X-linked inhibitor of apoptosis and glutamine synthetase were obtained from BD Biosciences Subsequently, the primary antibodies were retrieved and the membranes were washed by 600 µl Tris-buffered saline (TBS) for 3 times and 600 µl Tris-buffered saline with Tween-20 (TBST) for 2 times. Binding was detected using horseradish peroxidase-conjugated secondary antibodies (anti-rat/lamb/rabbit; Bio-Rad Laboratories, Inc.) for 1 h at room temperature and washed by TBST.
Immun-Star™ HRP peroxide buffer and the Immun-Star™ HRP luminol enhancer (Cat#94547; Bio-Rad Laboratories, Inc.) in a 1:1 volume ratio was used for enhanced chemiluminescent assay. The luminescent images were captured using a ChemiDoc XRS system (Bio-Rad Laboratories, Inc.) and the images were quantified and calculated by Quantity One 4.5.0 software based on the global median subtraction to decrease the variation between the batches of experiments.
Finally, the antibodies were eluted from the nitrocellulose membranes using Restore™ Western Blot stripping buffer (Cat# 21059; Thermo Fisher Scientific, Inc., Waltham, MA, USA). The thoroughly cleaned membranes were blocked again using 3% BSA solution for 1 h and re-analyzed as aforementioned.
Statistical analysis. The Student's t-test and the χ 2 test were used to evaluate the relationship between the clinicopathological factors and drug resistance of patients. A Spearman test was performed to determine the association between the different T and N stages, and chemotherapy resistance. The Significance Analysis of Microarray (SAM; http://www-stat. stanford. edu/~tibs/SAM/) software was used to screen differentially expressed proteins, and the further clustering and discriminant analysis for proteins were performed using k-fold cross-validation and hierachical clustering analysis (htt://linus.nci.nih.gov/BRB-ArrayTools.html) of BRB Array Tools v.3.3.0. SPSS 17.0 (SPSS v17.0 software; SPSS, Inc., Chicago, IL, USA) was used to identify the relationship between the PPA and the clinical data. P<0.05 indicated a statistically significant difference. The Ingenuity Pathway Analysis (IPA), version 9.0 (Ingenuity Systems, Inc., Redwood City, CA, USA) was used for pathway analysis.
Results

General and pathological characteristics of subjects.
The clinical data and pathological characteristics of patients are shown in Table I . According to the evaluation criteria of postoperative disease-free survival, 73 patients had a disease-free interval <12 months and were designated as the chemotherapyresistant group; while 67 patients with a disease-free survival of >36 months, were designated as the chemotherapy-sensitive group. The preoperative average age was 60.5 years old, and the global sex distribution was 5.1:1. No significant difference was found in age, sex distribution family history of cancer, the ratio of radical subtotal gastrectomy, histopathological grade, vascular invasion, tumor location and depth of invasion between chemoresistant and chemosensitive patients (p=0.726, p=0.494, p=0.644, p=0.085, p=0.159, p=0.444, p=0.728 and p=0.525, respectively). The tumor size of chemoresistant patients was bigger than that of chemosensitive patients (p=0.041), and the Table II . Differentially expressed proteins between chemosensitive and chemoresistant gastric cancer. number of malignant nodes of chemoresistant patients was more than that of chemosensitive patients (p<0.001). There was a significant difference in mortality, which was 6.0% in the chemosensitive group and 91.8% in the chemoresistant group (p<0.001). (Fig. 1) . The hierarchical clustering analysis of 23 proteins performed by BRB is shown in Fig. 2 .
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Differentially expressed proteins in signaling pathways
Logistic regression model for chemotherapy response.
Univariate logistic regression analysis revealed that 15 proteins, including PLK1, FKHR, HDAC1, WT1, CDK4, HMG-1, NMT1, Bcl-xL, H-Ras, ERCC1, ADH, P-JNK, DACH1, cytokeratin 18 and E-cadherin, as well as 2 clinicopathologic factors of AJCC-N and AJCC-TNM stages, had significant association with chemotherapy response.
The multivariate logistic regression analysis was used to determine the independent predictors associated with chemotherapeutic sensitivity in human gastric cancer. The results in Table III revealed that PLK1, DACH1, E-cadherin, FKHR, ADH and ERCC1 could be the independent predictors. The Cox and Snell R 2 and Nagelkerke R 2 in the logistic model were 0.571 and 0.762, respectively.
The ROC curve analysis of 6 independent factors revealed the overall predictive value with a AUC of 96%, which was higher than the area of a single predictor (61-83%). This indicated the good prediction efficiency of the predictive risk score model (Fig. 3) .
Moreover, the Risk Assessment System (RAS) of chemotherapy resistance in gastric cancer was built: Risk score = e z /(1+e z ) x 100; Where e denotes the natural logarithm; Z is the results of logistic regression; B0 represents the logistic regression coefficient for the constant; 'v1…vn' is the independent variable for multivariate regression; 'B1…Bn' is the regression coefficient corresponding to 'v1…vn'. Fig. 4A revealed that most of the patients had a risk score of 0-20 and 80-100, and the risk of chmoresistance increased according to the increased risk score (Fig. 4B) .
Therefore, all of the patients were subjected to 3 groups: the high-risk group with a risk score of >80, and a high risk of chemotherapeutic resistance; the medium-risk group with a risk score between 20-80, and a moderate risk of chemotherapeutic resistance; the low-risk group with a risk score of <20, and a low risk of chemotherapeutic resistance (Fig. 4C) . Finally, the RAS was validated in each subject. The results revealed that a total of 87.9% samples were correctly predicted, among which, 89.6% were correct in the chemosensitive group, and in the chemoresistant group, 86.3% of cases were predicted correctly (data not shown).
IPA system and the signaling pathways associated with chemotherapeutic sensitivity in gastric cancer. To identify the roles of differentially expressed proteins in the signal transduction pathway contributing to chemotherapy resistance in gastric cancer, the IPA system (version 9.0) revealed that 23 proteins were mainly participated in 5 types of signaling pathways (Fig. 5A) , such as cancer, cell cycle (12 proteins) and cell death and survival, cellular growth and proliferation (10 proteins). Two significant signaling networks with the most differentially expressed proteins are shown in Fig. 5B and C and each node in the network indicated a classic signaling pathway. In addition, the top 30 signaling pathways (p<0.01) with the highest correlation are shown in Fig. 5D , such as ErbB signaling, p53 signaling, 14-3-3-mediated signaling, and the PTEN signaling. 
Discussion
More individualized treatment regimens to decrease side-effects induced by adjuvant chemotherapy may be essential and the molecular mechanisms underlying resistance to chemotherapeutic drugs was widely investigated (16) .
In the present study, the PPA method was used to explore the underlying mechanisms of chemoresistance in gastric cancer. The results revealed that 23 proteins obtained between 73 chemotherapy-resistant patients and 67 chemotherapy-sensitive patients were mainly associated with cell adhesion, proliferation, migration, cell cycle, cell signaling and interaction. In addition, 11 proteins distinguished 2 groups of patients with an accuracy of 89.3%, a sensitivity of 90.3% and a specificity of 88.2%. These results may help surgeons to classify the gastric cancer tissues into chemotherapy sensitive and chemotherapy resistant. The differentially expressed proteins identified in the present study were consistent with various studies. For example, calpain, ERCC1 and β3 tubulin were observed to be highly expressed in gastric cancer cells resistant to chemotherapeutic agents (17) (18) (19) , while E-cadherin and DACH1 were lowly expressed (20, 21) . This may indicate the prediction features of proteins in chemotherapy drug-resistance. Since single predictors usually do not provide accurate predictions at the individual-level, the multivariable risk prediction model which included multiple predictors, facilitates clinical decision-making (22) . The similar prediction models were built in various types of cancer, such as lung cancer (23, 24) . The PPA analysis built a predictive model for chemoresistance based on the protein expression profiling. Moreover, the efficacy and the good prediction strength was explained. This model may help to predict drug resistance to chemotherapeutic agents in gastric cancer patients with high specificity and sensitivity.
Previous studies have demonstrated the correlation between chemotherapy resistance in gastric cancer tissues and a large number of aberrantly expressed proteins in signal transduction pathways, such as protein phosphorylation (25) , methylation (8) and aberrant expression (9) . IPA is commonly used to combine differentially expressed genes with associated-networks, functions and canonical pathways (26) . The results revealed that the differentially expressed proteins were mainly associated with cell actions, cancers and cell signaling and interaction. Moreover, the ErbB, p53 and 14-3-3-mediated signaling, and the PTEN signaling pathway were enriched by 23 differentially expressed proteins. This is consistent with previous studies that revealed that chemoresistance in cancer is mediated via various signaling pathways (27) (28) (29) (30) .
Our results revealed that multiple signaling pathways and proteins were involved in chemotherapy and chemotherapy resistance in gastric cancer. The phosphorylation, methylation and aberrant expression of proteins are closely related to the chemoresistance of gastric cancer. The predictive risk model established by PPA technique, the model classifier and the logistic regression for chemoresistance are feasible, and could have important clinical implications in predicting the chemoresistance in radically resected gastric cancer patients.
